Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	755.32B -9.0%
Revenue (ttm)	241.80B +0.1%
Net Income	21.84B +95.0%
EPS	3,398.79 +111.2%
Shares Out	7.02M
PE Ratio	31.66
Forward PE	28.65
Dividend	1,200.00 (1.12%)
Ex-Dividend Date	Sep 29, 2025

Volume	41,013
Average Volume	52,539
Open	106,700
Previous Close	105,700
Day's Range	106,700 - 109,500
52-Week Range	105,500 - 182,700
Beta	0.32
RSI	31.61
Earnings Date	Mar 20, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 718
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.